NewAmsterdam Pharma Advances Obicetrapib Development with Promising Alzheimer's Biomarker Data and Multiple Phase 3 Trials
Key Insights
NewAmsterdam Pharma reported encouraging MACE event rates in its PREVAIL cardiovascular outcomes trial, tracking in line with Phase 3 BROADWAY results, with EMA approval decision expected in second half 2026.
The company demonstrated statistically significant reductions in p-tau217 (search), a key Alzheimer's disease (search) biomarker, with obicetrapib showing 20.5% reduction in highest-risk ApoE4 (search)/E4 carriers over 12 months.
Three Phase 3 trials are ongoing including PREVAIL (9,500+ patients), REMBRANDT (coronary plaque imaging), and newly initiated RUBENS for metabolic syndrome (search) patients.
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) has outlined significant progress in its obicetrapib development program, highlighting encouraging cardiovascular outcomes data and breakthrough findings in Alzheimer's disease (search) biomarkers that could expand the therapeutic potential of its cholesteryl ester transfer protein (search) (CETP (search)) inhibitor.
The late-stage biopharmaceutical company reported that its Phase 3 PREVAIL cardiovascular outcomes trial is showing promising early signals, with overall MACE (major adverse cardiovascular events) rates tracking in line with those observed in the completed Phase 3 BROADWAY trial. CEO Michael Davidson, M.D., expressed encouragement about the blinded 12-month event rate data from the trial, which enrolled over 9,500 patients with atherosclerotic cardiovascular disease (search) whose LDL cholesterol (search) remains inadequately controlled despite maximally tolerated lipid-lowering therapy.
Regulatory Progress and Commercial Preparations
NewAmsterdam's partner A. Menarini International Licensing S.A. (search) has secured acceptance from the European Medicines Agency (EMA) for marketing authorization applications covering both obicetrapib 10 mg monotherapy and a 10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination. The applications target patients with primary hypercholesterolemia (search), including both heterozygous familial and non-familial or mixed dyslipidemia cases. An EMA approval decision is anticipated in the second half of 2026, with commercial launch preparations underway contingent upon regulatory approval.
Breakthrough Alzheimer's Disease Findings
In a significant development beyond cardiovascular applications, NewAmsterdam reported statistically significant reductions in p-tau217 (search), a key biomarker of Alzheimer's disease (search) pathology, from a prespecified analysis of the BROADWAY trial. The analysis encompassed 1,535 patients, including 367 ApoE4 (search) carriers, and demonstrated meaningful biomarker improvements across multiple patient populations.
The most striking results emerged in ApoE4 (search)/E4 carriers, representing the highest risk category for Alzheimer's disease (search), where obicetrapib reduced p-tau217 (search) levels by 20.5% over 12 months compared to placebo (p=0.010, n=29). The full analysis set showed statistically significant reductions (p<0.002, n=1,515), while ApoE4 carriers demonstrated significant improvements (p=0.0215, n=367).
These findings, published in the Journal of Prevention of Alzheimer's Disease (search) in October 2025, suggest an emerging link between CETP (search) inhibition and neurodegeneration. Based on these results, NewAmsterdam plans to initiate its first dedicated Alzheimer's disease trial in 2026, potentially demonstrating obicetrapib's ability to modify key biomarkers and clinical pathology of the condition.
Expanding Clinical Development Portfolio
The company is advancing three concurrent Phase 3 trials beyond PREVAIL. The REMBRANDT trial utilizes coronary computed tomography angiography imaging to evaluate the effect of obicetrapib plus ezetimibe fixed-dose combination on coronary plaque in adult participants with high-risk atherosclerotic cardiovascular disease (search). This placebo-controlled, double-blind, randomized trial assesses the impact of daily obicetrapib 10 mg plus ezetimibe 10 mg on coronary plaque and inflammation characteristics, with enrollment of approximately 300 patients expected to complete in 2026.
The newly initiated RUBENS trial, which enrolled its first patients in December 2025, will evaluate obicetrapib alone or combined with ezetimibe in patients with type 2 diabetes (search) or metabolic syndrome (search) requiring additional LDL cholesterol (search) lowering despite available therapy. The trial expects to enroll approximately 300 patients, with topline data anticipated by year-end 2026. If successful, RUBENS could enable additional label enhancements for patients with Type 2 diabetes and/or metabolic syndrome not achieving their LDL cholesterol risk-based goals.
Addressing Unmet Medical Need
Cardiovascular disease (search) remains the leading cause of death globally despite available lipid-lowering therapies. The company notes that 30 million under-treated U.S. adults are not at their risk-based LDL cholesterol (search) goals, including 13 million with atherosclerotic cardiovascular disease (search). Less than one in four patients with atherosclerotic cardiovascular disease achieve an LDL cholesterol goal below 70 mg/dL, and only 10% of very high-risk patients reach the target below 55 mg/dL.
Obicetrapib represents a novel approach as an oral, low-dose, once-daily CETP (search) inhibitor designed to overcome limitations of current LDL-lowering treatments. Across multiple Phase 2 and Phase 3 trials, including ROSE2, TULIP, ROSE, OCEAN, BROOKLYN, BROADWAY, and TANDEM, the company has observed statistically significant LDL-lowering combined with a side effect profile similar to placebo.
Financial Position and Strategic Outlook
NewAmsterdam reported an unaudited cash, cash equivalents, and marketable securities balance of approximately $729 million as of December 31, 2025. The company believes this funding will support operations through the anticipated PREVAIL cardiovascular outcomes trial readout and subsequent U.S. commercial launch, if approved.
The company continues developing a portfolio of obicetrapib-based combinations, conducting studies to guide future proprietary fixed-dose combination development. Following successful completion of Phase 3 BROADWAY, TANDEM, and BROOKLYN trials, NewAmsterdam plans to announce additional data from these studies relating to both obicetrapib monotherapy and the fixed-dose combination with ezetimibe.